Bailong Chuangyuan(SH:605016) Xinda Securities·2025-07-14 01:21Investment Rating - The investment rating for the company is "Buy" [1][2][4]. Core Insights - The company achieved record high revenue and profit in Q2, with a revenue of 336 million yuan, up 20.49% year-on-year, and a net profit of 89.17 million yuan, up 35.07% year-on-year [2][4]. - The approval of D-Alulose as a new food ingredient in China is expected to open the domestic market, potentially increasing revenue from health sweeteners [4]. - The establishment of a new factory in Thailand aims to leverage lower raw material costs and enhance production capacity for various products, supporting international market expansion [4]. - Profit forecasts have been raised, with expected EPS for 2025-2027 at 0.84, 1.09, and 1.42 yuan, respectively, maintaining a "Buy" rating [4]. Financial Performance Summary - For H1 2025, the company reported a total revenue of 650 million yuan, a year-on-year increase of 22.29%, and a net profit of 171 million yuan, up 42.68% [2][4]. - The gross profit margin is projected to improve, with estimates of 38.2% in 2025 and 37.4% in 2026 [5]. - The company’s total revenue is expected to grow from 868 million yuan in 2023 to 2.448 billion yuan in 2027, reflecting a compound annual growth rate [5]. - The net profit is forecasted to increase from 193 million yuan in 2023 to 598 million yuan in 2027, indicating strong growth potential [5].